217 results
Page 2 of 11
8-K
EX-99.1
xa14xa5yd6bedl zj
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
k41hwo
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
EX-99.1
4h4ev6yjt ntsw
4 Oct 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
8:30am
8-K
EX-99.1
k6cc s58ccb
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
8-K
EX-99.1
cw282okg
31 Aug 23
Kineta to Participate in Upcoming Investor Conferences
9:30am
8-K
EX-99.1
oi0h1j4tc
11 Aug 23
Regulation FD Disclosure
4:08pm
8-K
EX-99.1
ahhpf7gb6cr6p2
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
yjt du13m55
29 Jun 23
Kineta to Receive $5 Million Milestone Payment from Merck
7:01am
8-K
EX-99.1
zugsp
28 Jun 23
Departure of Directors or Certain Officers
7:00am
424B3
v8zl5m i2c8728t84qf
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-99.1
9nsd96bcxsp9p2qlccz1
9 Jun 23
Submission of Matters to a Vote of Security Holders
9:00am
8-K
EX-99.1
yciw6wh4
24 May 23
Regulation FD Disclosure
9:30am
8-K
EX-99.1
se2tu31c8
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am
8-K
EX-99.1
caht4v1
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
8-K
EX-99.1
wxtdaqv
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
37m8 e0ocep5
21 Apr 23
Prospectus supplement for primary offering
5:14pm